注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Nexalin Technology Inc从事设计和开发针对心理健康流行病的神经刺激产品。该公司开发了一种易于管理的第1代或第1代医疗设备,利用生物电子医疗技术治疗焦虑和失眠,无需药物或心理治疗。该公司还正在设计使用Gen-2治疗物质使用障碍的临床试验,特别是与阿片类药物、慢性疼痛、阿尔茨海默病和痴呆症相关的物质滥用问题。该公司的产品是非侵入性和不可检测的,可以为那些受精神健康问题困扰的人提供缓解而没有不良副作用。其变化的电压、电流、电磁场和各种频率的设计称为波形。该公司的设备产生高频、电荷平衡的电流波形,应用于头部的电极阵列。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Gian Domenico Trombetta | 63 | - | Member of Strategic Advisory Board |
Tucker Andersen | - | - | Member of Strategic Advisory Board |
Leonard A. Osser | 77 | - | Member of Strategic Advisory Board |
Leslie Bernhard | 80 | 2023 | Independent Chairperson of the Board |
Ben V. Hu | 67 | - | Independent Director |
Irene Cergnul | - | - | Member of Medical Advisory Board |
Abraham Scheer | - | - | Member of Medical Advisory Board |
William A. Hudson | - | 2024 | Member of Military & Government Advisory Board |
Alan Kazden | 63 | 2019 | Independent Director |
Nancy White | - | - | Member of Medical Advisory Board |
Mark White | 62 | 2018 | President, CEO, CFO & Director |
David Owens | 63 | 2017 | Chief Medical Officer & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核